Objective outcome measures: Collecting meaningful data on alopecia areata

Elise A. Olsen; Janet Roberts; Leonard Sperling; Antonella Tosti; Jerry Shapiro; Amy McMichael; Wilma Bergfeld; Valerie Callender; Paradi Mirmirani; Ken Washenik; David Whiting; George Cotsarelis; Maria Hordinsky

doi:10.1016/j.jaad.2017.10.048

Objective outcome measures: Collecting meaningful data on alopecia areata

Elise A. Olsen, Janet Roberts, Leonard Sperling, Antonella Tosti, Jerry Shapiro, Amy McMichael, Wilma Bergfeld, Valerie Callender, Paradi Mirmirani, Ken Washenik, David Whiting, George Cotsarelis, Maria Hordinsky

Dermatology

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Background: Although alopecia areata is a common disorder, it has no US Food and Drug Administration–approved treatment and evidence-based therapeutic data are lacking. Objective: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. Methods: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. Results: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. Limitations: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. Conclusion: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.

Original language	English (US)
Pages (from-to)	470-478.e3
Journal	Journal of the American Academy of Dermatology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.jaad.2017.10.048
State	Published - Sep 2018

Bibliographical note

Funding Information:
Supported in part by the Duke University Hair Disorders Research and Treatment Center and the Leirion Foundation.

Publisher Copyright:
© 2017 American Academy of Dermatology, Inc.

Keywords

ALODEX score
SALT score
alopecia areata
assessment measures
outcome measures
response criteria

Publisher link

10.1016/j.jaad.2017.10.048

Find It

Find It at U of M Libraries

Cite this

Olsen, E. A., Roberts, J., Sperling, L., Tosti, A., Shapiro, J., McMichael, A., Bergfeld, W., Callender, V., Mirmirani, P., Washenik, K., Whiting, D., Cotsarelis, G., & Hordinsky, M. (2018). Objective outcome measures: Collecting meaningful data on alopecia areata. Journal of the American Academy of Dermatology, 79(3), 470-478.e3. https://doi.org/10.1016/j.jaad.2017.10.048

Olsen, EA, Roberts, J, Sperling, L, Tosti, A, Shapiro, J, McMichael, A, Bergfeld, W, Callender, V, Mirmirani, P, Washenik, K, Whiting, D, Cotsarelis, G & Hordinsky, M 2018, 'Objective outcome measures: Collecting meaningful data on alopecia areata', Journal of the American Academy of Dermatology, vol. 79, no. 3, pp. 470-478.e3. https://doi.org/10.1016/j.jaad.2017.10.048

@article{eb2cc5c0c33a45abb73fbb8491a7fc5c,

title = "Objective outcome measures: Collecting meaningful data on alopecia areata",

abstract = "Background: Although alopecia areata is a common disorder, it has no US Food and Drug Administration–approved treatment and evidence-based therapeutic data are lacking. Objective: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. Methods: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. Results: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. Limitations: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. Conclusion: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.",

keywords = "ALODEX score, SALT score, alopecia areata, assessment measures, outcome measures, response criteria",

author = "Olsen, {Elise A.} and Janet Roberts and Leonard Sperling and Antonella Tosti and Jerry Shapiro and Amy McMichael and Wilma Bergfeld and Valerie Callender and Paradi Mirmirani and Ken Washenik and David Whiting and George Cotsarelis and Maria Hordinsky",

note = "Funding Information: Supported in part by the Duke University Hair Disorders Research and Treatment Center and the Leirion Foundation. Publisher Copyright: {\textcopyright} 2017 American Academy of Dermatology, Inc.",

year = "2018",

month = sep,

doi = "10.1016/j.jaad.2017.10.048",

language = "English (US)",

volume = "79",

pages = "470--478.e3",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Objective outcome measures

T2 - Collecting meaningful data on alopecia areata

AU - Olsen, Elise A.

AU - Roberts, Janet

AU - Sperling, Leonard

AU - Tosti, Antonella

AU - Shapiro, Jerry

AU - McMichael, Amy

AU - Bergfeld, Wilma

AU - Callender, Valerie

AU - Mirmirani, Paradi

AU - Washenik, Ken

AU - Whiting, David

AU - Cotsarelis, George

AU - Hordinsky, Maria

N1 - Funding Information: Supported in part by the Duke University Hair Disorders Research and Treatment Center and the Leirion Foundation. Publisher Copyright: © 2017 American Academy of Dermatology, Inc.

PY - 2018/9

Y1 - 2018/9

N2 - Background: Although alopecia areata is a common disorder, it has no US Food and Drug Administration–approved treatment and evidence-based therapeutic data are lacking. Objective: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. Methods: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. Results: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. Limitations: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. Conclusion: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.

AB - Background: Although alopecia areata is a common disorder, it has no US Food and Drug Administration–approved treatment and evidence-based therapeutic data are lacking. Objective: To develop guidelines for the diagnosis, evaluation, assessment, response criteria, and end points for alopecia areata. Methods: Literature review and expert opinion of a group of dermatologists specializing in hair disorders. Results: Standardized methods of assessing and tracking hair loss and growth, including new scoring techniques, response criteria, and end points in alopecia areata are presented. Limitations: The additional time to perform the assessments is the primary limitation to use of the methodology in clinical practice. Conclusion: Use of these measures will facilitate collection of standardized outcome data on therapeutic agents used in alopecia areata both in clinical practice and in clinical trials.

KW - ALODEX score

KW - SALT score

KW - alopecia areata

KW - assessment measures

KW - outcome measures

KW - response criteria

UR - http://www.scopus.com/inward/record.url?scp=85051389890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051389890&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2017.10.048

DO - 10.1016/j.jaad.2017.10.048

M3 - Article

C2 - 29128463

AN - SCOPUS:85051389890

VL - 79

SP - 470-478.e3

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -

Objective outcome measures: Collecting meaningful data on alopecia areata

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this